, although the magnitude of DVT/ PE risk may not be the same in Proteus syndrome and PROS. PROS has phenotypic overlap with Proteus syndrome, but is caused by somatic mutations in PIK3CA, which is in the same signaling pathway as AKT1 (Keppler-Noreuil et al., 2014; Kurek et al., 2012; Lindhurst et al., 2012) . Furthermore, there are multiple reports of patients with isolated congenital vascular malformations not FIGURE 1 A 6.5-year-old boy with Proteus syndrome, (a) developing cerebriform connective tissue nevus of the left foot, and bony overgrowth of bilateral feet and toes, (b) venous malformations with bony overgrowth of legs and feet, (c) bony overgrowth and distortion of the fingers, and capillary malformations of the fingers and hands. associated with an underlying syndrome that have increased risk of DVT and PE (Dompmartin et al., 2008; Enjolras, Ciabrini, Mazoyer, Laurian, & Herbreteau, 1997; Mason et al., 2001; Mazoyer et al., 2008; Mazoyer, Enjolras, Laurian, Houdart, & Drouet, 2002; Merli, 2005; Oduber, Gerdes, van der Horst, & Bresser, 2009) . However, in all these conditions, the underlying mechanism for increased risk of thromboembolism remains unknown. To better understand the natural history of DVT and PE and potential causative factors, we set out to evaluate the largest cohort of patients with Proteus syndrome for these complications. We present the clinical findings in 57 individuals with Proteus syndrome, including relevant history, physical examination, radiologic, and laboratory results of the hematologic evaluations. The purposes of this study were to identify potential risk factors for thrombosis in Proteus syndrome, which would form the basis for future etiologic investigations of DVT and PE.
| METHODS
Fifty-seven patients with Proteus syndrome were evaluated at the National Institutes of Health between 1997 and 2012, as part of a natural history study approved by the National Human Genome Research Institute (NHGRI) IRB (study # 04-HG-0132). Written informed consent from participants or their guardians was obtained. All met clinical diagnostic criteria for Proteus syndrome (Biesecker, 2006; Biesecker et al., 1999) . Fifty-two of the 57 patients had the somatic activating mutation, c.49G > A, p.
Glu17Lys in AKT1 confirmed from the affected tissue samples (data not shown). For the 10 of the 57 patients who were deceased, the cause of death was recorded. Of the remaining 47 patients with Proteus syndrome, their medical records were reviewed for relevant findings, medical course, history of superficial and deep venous thromboembolic events, use of anticoagulants, comorbidity, and whether they had a hematology consultation including D-dimer levels, coagulation testing, and pertinent radiologic studies for example, Doppler ultrasounds of the extremities and CT scan of the chest. Components of the hypercoagulable studies included: PT, PTT, antithrombin III activity, Factor V Leiden mutation, fibrinogen, lupus anticoagulant, Protein C and S activities, prothrombin mutation, c.*97G > A, (G20210A) in F2, thrombin time, and homocysteine. The D-dimer assay used at the NIH is the STA Liatest (Diagnostica Stago, Parsippany, NJ), which has been validated for screening in the general population with a threshold of 0.5 mcg/ml (Aguilar et al., 2002; Kulstad, Kulstad, & Lovell, 2004; Rathbun, Whitsett, & Raskob, 2004) . Of the 17 patients who had D-dimer levels, eight had an abnormal level (Figure 3 ). Three with elevated levels (0.69, 0.6, 0.7 μg/ml) had no evidence of DVT/PE, on the basis of a normal Doppler ultrasound of the legs and CT scan of the chest (ages 6, 42, and 32 years, respectively). Five individuals had levels >1 mcg/ml (1.14, 2.09, 2.17, 2.64, 3.19 mcg/ml), four had positive findings of DVT and/or PE, and one had recurrent superficial thrombi. Six individuals with median age 16.5 years were diagnosed with DVT (two also had PE) after surgery (of the spine in one and of affected limb in four); one was recurrent. Two of these individuals did not have D-dimer levels (Table 1) . Seven patients had other venous abnormalities. These venous abnormalities were: enlarged portal venous malformation, phlebitis and extensive varicosities, phleboliths, underdevelopment of the deep venous system in the leg, and superficial venous thromboses.
| DISCUSSION
This retrospective cohort study confirms the conclusions of earlier case reports of an increased risk for DVT and/or PE in individuals with Proteus syndrome (Eberhard, 1994; Skovby et al., 1993; Slavotinek et al., 2000; Staub et al., 2006) . These reports included six individuals with Proteus syndrome, who developed pulmonary or portal thromboembolism, two postoperatively, all with ages <27 years, and all but one fatal. It has been suggested that the vascular malformations are the primary risk factor for thromboembolism in patients with Proteus syndrome (Slavotinek et al., 2000) , but other risk factors have not been investigated. In this review of the clinical, radiological, and laboratory evaluations of a large cohort of patients with Proteus syndrome, we found that six of ten deaths (60%) were the result of a DVT and bilateral PE at a young age (median age of 17 years), and among living patients, that six of 47 (16%) had DVTs, with three of the six having co-occurrence of PE, and another 7 of 47 (15%) had evidence of thrombophlebitis and other venous malformations. We also know that among the 10 deceased patients that DVT and PE occurred in several patients, some perioperative, and some associated with acute illnesses. This younger age and frequency of superficial venous thromboses, DVT, and PE in patients with Proteus syndrome is striking. Among the 47 currently living patients, the recognized DVT/PE events occurred postoperatively in an affected (overgrown) limb. In addition, venous varicosities were visible on examination in half of these patients. We found that the occurrence of thrombosis in patients with Proteus syndrome was not primarily attributable to an increase in any one of the well-known prothrombotic conditions such as factor V Leiden, prothrombin mutation, c.*97G > A, (G20210A) in F2, deficiency of antithrombin III, protein C, or protein S, that typically increase the rate of thrombin production and fibrin clot generation. While we recognize that a study of this size is limited in power, the high frequency of DVT and PE in Proteus syndrome argues against these being major factors, because they are relatively uncommon. Therefore, our findings point to other potential mechanisms for thromboembolism in Proteus syndrome. We speculate that the biology of Proteus syndrome may have adverse effects on hemostasis by other mechanisms, such as endothelial abnormalities or platelet dysfunction, beyond the wellrecognized effects of stasis associated with vascular malformations.
Indeed, this strikingly high rate of DVT and PE in patients with
Proteus syndrome lead us to speculate that this disorder may have a level of risk that is out of proportion to the vascular malformations and may be attributable to specific vascular and/or platelet dysfunction caused by the AKT1 p.E17 K mutation.
The D-dimer is a widely used and sensitive screening test for venous thrombosis (Lees, Griffiths, Paxton, & Wahbi, 2011; Molugu, Fisher, Hirons, Hughes, & Raftery, 2013; Wells et al., 2003) . D-dimer is a circulating fibrin degradation product that forms when a thrombus is degraded by thrombin, coagulation factor XIIIa, and fibrinolysin (Molugu et al., 2013; Wedlund & Voslar, 2014; Wells, 2004) . The D-dimer levels reflect endogenous fibrinolysis, which may be used as a marker of DVT (Lees et al., 2011) . In this study, of the 8 of 17 individuals with Proteus syndrome who had D-dimer levels, four of eight (50%) with levels >1 mcg/dl had thrombotic events. In contrast, none of three patients with a level between 0.5 and 1.0 had a DVT or PE detectable by imaging.
If we assume that the individuals with a D-dimer level of <0.5 mcg/ml did not have a DVT or PE, this yields a sensitivity of 100% and a PPV of 37% (4/11). This compares favorably with the performance of the D-dimer test as a DVT/PE screen in the general population with suspected DVT, which has a PPV of ∼20-30% and a sensitivity of ∼96% (we assume here that all of the patients reported here with a D-dimer <0.5 mcg/ml did not have DVT or PE) (Nelson, Wright, Silbaugh, & Cota, 2009; Pulivarthi & Gurram, 2014) . We conclude that the D-dimer test is useful in patients with Proteus syndrome and should be used liberally. What is less clear is whether the screening threshold used in this context should be the same FIGURE 3 Abnormal D-dimer levels in 8 of 17 patients with Proteus syndrome, four of which had deep venous thromboembolism and/or pulmonary embolism.
as it is for the general population (which is 0.5 mcg/ml for the STA Liatest D-dimer assay). CHEST Guideline and Expert Panel Report) (Kearon et al., 2016) .
Thromboembolism has also been reported in patients with PROS, which subsumes the previous phenotypic descriptors of CLOVES syndrome, KTS (Alomari et al., 2010; Keppler-Noreuil et al., 2014; Mirzaa, Conway, Graham, & Dobyns, 2013) , and other phenotypes.
Oishi & Ezaki (2010) described three preadolescent patients with the clinical diagnosis of KTS who had large upper extremity venous malformations and developed DVT; two had documented PE, one of which was fatal. The specific pathogenesis for thromboembolism in PROS is also unknown, although the presence of vascular malformations as a risk factor is assumed, as for Proteus syndrome, and these disorders are both caused by somatic mutations in the PI3K-AKT signaling pathway. The p110α catalytic subunit of PI3 K is essential for endothelial cell migration and angiogenesis, and sustained endothelial activation of AKT1 has been shown to induce the formation of structurally and functionally abnormal blood vessels (Graupera et al., 2008; Phung et al., 2006) . In addition, RAS activation in endothelial cells resulted in abnormal vascular morphogenesis, which is regulated by PI3 K signaling (Bajaj, Zheng, Adam, Vincent, & Pumiglia, 2010) . There are also many reports of other patients with congenital vascular malformations not associated with an underlying syndrome who have increased prevalence of thromboembolism (Dompmartin et al., 2008; Enjolras et al., 1997; Mason et al., 2001; Mazoyer et al., 2002; Merli, 2005; Oduber et al., 2009) . Of course, it is possible that many of these reports of patients with presumed non-syndromic vascular malformations may in fact have an undiagnosed or subclinical form of Proteus syndroem or PROS. It is therefore possible that the risk of DVT and PE is substantially attributable to dysfunction of the AKT/PI3 K pathway.
In general, the three primary clinical factors associated with thrombosis risk include those comprising Virchow's triad: 1) vessel wall damage due to inflammation or trauma; 2) changes in blood flow or volume due to immobility, ischemia, or other conditions; and 3) hypercoagulable factors present in the blood, including inherited and acquired coagulation disorders (Merli, 2005) including, decreased fibrinogen, elevated D-dimer, elevated prothrombin times and normal to low platelet counts (Oduber et al., 2009) . In several studies, the severity of the coagulopathy correlated with the extent of the malformation (Enjolras et al., 1997; Mason et al., 2001; Mazoyer et al., 2002) . Of course, the Virchow's triad model of pathogenesis was proposed long before the molecular delineation of the causes of vascular malformations. It is now recognized that mosaicism is not as rare as previously supposed (Biesecker & Spinner, 2013) and that many vascular malformations are caused by mosaic mutations of the AKT/PI3 K pathway. We hypothesize that the outsize risk of DVT/PE in patients with Proteus syndrome, the elevated risk in patients with PROS, coupled with a speculation that many apparently non-syndromic vascular malformations are also due to mosaic mutations in this pathway, all point to AKT/PI3 K pathway being a fourth major underlying factor of susceptibility to DVT and PE.
We conclude that patients with Proteus syndrome have a striking predisposition to DVT and PE and that liberal use of the D-dimer test as a screen for these complications is useful, as it can identify patients, including young children, who can benefit from anticoagulation. While most DVT and PE in patients with Proteus syndrome developed perioperatively, others did not, and clinicians must maintain a high index of suspicion, especially since DVT and PE are rare in children who do not have Proteus syndrome. We suggest that D-dimer is a useful screen for the presence of a DVT in patients with Proteus syndrome when the level is above 0.5 mcg/dl (for the STA Liatest D-dimer assay). To better understand the diagnosis, management, etiology, genetic mechanisms, and natural history of thromboembolism in Proteus syndrome and related disorders, including PROS, we plan to undertake several efforts. First, we will establish a registry to collect data on D-dimer screening and subsequent evaluations for all patients with Proteus syndrome or PROS. We also plan to conduct a prospective evaluation of clinical, radiological, and laboratory studies, and contribute to development of therapeutic approaches for these disorders. Using these approaches, we are optimistic that we can lower the morbidity and mortality of Proteus syndrome and PROS.
